Belgian Multidiscplinary Immunotoxicity Board (BITOX)
Aim: share experiences, standardize approach for irAEs and find clinically relevant research questions
Online questionnaire
approx. 5 minutes to fill in case details
Click here to fill in case details
via smartphone
Please click the following links for a patient information flyer about BITOX in Dutch (NL) and French (FR).
Questions handled
- Diagnosis and management of severe immune related adverse events
- Starting immunotherapy in ‘dysimmune’ patients
- transplant patients
- patients with chronic (viral) infections
- patients with autoimmune disorders
- immunosuppressed patients
- rechallenge after irAE
- other
Bimonthly virtual meeting via Teams
- onco/hematologists, organspecialists and interested healthcare professionals
- Timing: 1st and 3rd Monday of each month 16:30-17:30
- if you are unable to attend, the case can still be discussed with a written recommendation provided
Abbrevations
IT: Immunotherapy for solid or hematological cancers
irAE: Immune Related Adverse Event
ICI: Immune Checkpoint Inhibition
Dysimmunity: having an characteristic which might influence IT outcome (eg underlying auto immune disease, having previous irAE, chronic viral infection, severe allergy, ….)
Click on the banner below for an introduction to BITOX (in French)
